Skip to Content Skip to Search
Older lady stood on balcony

COPD patient

About us

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

GSK employee in lab
Arthur, Oncology Scientist, US

We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.

Our values and expectations are at the heart of everything we do and help define our culture - so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work. 

Our values are Patient Focus, Transparency, Respect, Integrity.
Our expectations are Courage, Accountability, Development, Teamwork.

Doing more in the US

Across the US, we employ more than 15,000 people - from our Vaccines R&D headquarters in Maryland, to our R&D Hub in Pennsylvania, and from one of our nearly 10 manufacturing sites across America, our employees and our values are at the heart of everything we do. This work starts one person, one community, and one story at a time .

What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.


Pharma tcells
Immune system T-cells attacking a cancer cell


Science image
Herpes zoster virus of shingles

Consumer Healthcare

Novamin image
Novamin, a key technology in Sensodyne Repair and Protect

How we do it

Everyone at GSK is focused on three priorities – Innovation, Performance, Trust


We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

  • $5.1bn

    R&D investment in 2018

  • 33*

    of the 46* new medicines now in development targeting modulation of the immune system

  • 16*

    immuno-oncology assets now in clinical development


We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

  • $40.9bn

    total turnover in 2018

  • $11.5bn

    adjusted operating profit in 2018

  • $7.5bn

    free cash flow in 2018

  • $5.1bn

    dividends paid in 2018


We commit to ensuring the quality, safety and reliable supply of our products; and to building trust through our approach to engagement, pricing, global health and being a modern employer.

  • 78%

    employee engagement score on our latest employee survey

  • $297m

    donated in 2018 to community health programs

  • 1st

    in Access to Medicines Index since the assessment began in 2008